US20170304228A1 - New indication of cinacalcet hcl pharmaceutical composition for treating cancer - Google Patents

New indication of cinacalcet hcl pharmaceutical composition for treating cancer Download PDF

Info

Publication number
US20170304228A1
US20170304228A1 US15/521,504 US201515521504A US2017304228A1 US 20170304228 A1 US20170304228 A1 US 20170304228A1 US 201515521504 A US201515521504 A US 201515521504A US 2017304228 A1 US2017304228 A1 US 2017304228A1
Authority
US
United States
Prior art keywords
cancer
cinacalcet hcl
cell lines
cinacalcet
hcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/521,504
Inventor
Chiu-Hung Chen
Show-Mei CHUANG
Tzong-Der Way
Nai-Wan HSIAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Launx Biomedical Co Ltd
Original Assignee
Launx Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Launx Biomedical Co Ltd filed Critical Launx Biomedical Co Ltd
Priority to US15/521,504 priority Critical patent/US20170304228A1/en
Publication of US20170304228A1 publication Critical patent/US20170304228A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention related to a new indication of Cinacalcet hydrochloride (Cinacalcet HCl) pharmaceutical composition, especially related to inhibition effect of Cinacalcet hydrochloride (Cinacalcet HCl) pharmaceutical composition on a variety of cancer cells.
  • Cancer is the most popular disease cause of death in the world.
  • the cancer patients are gradually increase yearly, therefore the treatment method of the cancer has become an important issue.
  • the medical treatments of cancer can be classified as surgical treatment, radiation therapy, chemotherapy and target therapy.
  • the cancer drug is to inhibit cancer cells duplication and split to prevent the tumor growth and metastasis.
  • More attention of therapies is being focused on drugs or other substances that block the growth and spread of cancer by interfering with specific molecules (“molecular targets”) that are involved in the growth, progression, and spread of cancer. Averagely, only about five of 10,000 new drugs can successfully enter the phase I of clinical trials.
  • the manufacturing of the drug is still a big problem.
  • problems need to overcome, such as drug safety, patient selection, trial dose and other issues.
  • Even the drug has approved by the FDA and sales on the market, there still possibly face the situation of the poor drug response in patients.
  • the cancer patients happen the drug resistance, that would reduce the effectiveness of the drugs and result in the medical treatment failure. Therefore, the new drug development is very difficult.
  • Cinacalcet hydrochloride (Cinacalcet HCl) or calcimimetic is a naphthalene derivative and calcimimetic agent that increases the sensitivity of parathyroid gland calcium-sensing receptors to serum calcium.
  • Cinacalcet HCl is the orally bioavailable hydrochloride salt of the calcimimetic cinacalcet. Cinacalcet increases the sensitivity of calcium-sensing receptors on chief cells in the parathyroid gland to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. In other word, these actions could reduce parathyroid hormone secretion and decreases serum calcium in the treatment of parathyroid disease.
  • PTH parathyroid hormone
  • Cinacalcet HCl therapy was used for secondary hyperparathyroidism in hemodialysis patients. As a result, Cinacalcet HCl is approved by FDA and accumulated a huge data of drug use and drug mechanism research.
  • Cinacalcet HCl Due to the differences of the clinical use, there is no research present that the Cinacalcet HCl has any potential to inhibit cancer cell.
  • the present invention provides the development of new cancer clinical indications of Cinacalcet HCl.
  • the present invention provides a new indication of Cinacalcet HCl.
  • the experimental results showed that the Cinacalcet HCl had no toxicity or had little toxicity to normal cells in the present invention.
  • the selective effect of Cinacalcet HCl between normal cells and cancer cells need to be identified.
  • the present invention provides a pharmaceutical composition of Cinacalcet HCl for treating cancer.
  • the pharmaceutical composition is composed of effective dose of Cinacalcet HCl and a pharmaceutical acceptable salt.
  • the cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer.
  • the cancer is selected from osteosarcoma, skin cancer and blood cancer.
  • the pleural-related cancer is lung cancer.
  • the abdominal-related cancer is selected from bladder cancer, and cervical cancer.
  • the endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer.
  • the gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.
  • the effective dose of Cinacalcet HCl is from 10 mg/kg/day to 500 mg/kg/day.
  • FIG 1 shows the inhibitory effect of Cinacalcet HCl on the different cancer cells.
  • FIG. 2 shows the results of the inhibitory effect of tumor volume by Cinacalcet HCl.
  • FIG. 3 shows the inhibitory effect of tumor growth via administered high-dose and low-dose of Cinacalcet HCl.
  • the cancer cells includes lung cancer, gastric cancer, hepatic cancer, colon cancer, skin cancer, cervical cancer, prostate cancer, bladder cancer, breast cancer, leukemia, pancreatic cancer, ovarian cancer, tongue cancer, osteosarcoma, and renal cancer.
  • the normal cells used in the control group included kidney cell (HEK293) and human bronchial epithelial cell line BEAS-2B (as shown in Table 1).
  • Cancer cell lines were cultured in different culture medium according to different characteristics (as shown in Table 1). The cell numbers were counted and reseed as 2 ⁇ 10 6 in culture plate/flask. Then, the culture medium were added to a volume of 10 ml, and the cells were cultured for 2-3 days. Then, the cells were suspended for loading into 96-well plates. The number of cells was 3000 and the volume of the culture medium was 100 ⁇ l each well.
  • This inhibition test of Cinacalcet HCl on pleural-related cancer cells were using two lung cancer cell lines A549 and H1650.
  • the inhibitory tests of Cinacalcet HCl were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 2.
  • This inhibition test of Cinacalcet HCl on abdominal-related cancer cells were using bladder cancer cell line TSGH and T24 (Table 3), cervical cancer cell lines HeLa and C-33A (Table 4), renal cancer cell line 786-O (Table 5).
  • the inhibitory tests of Cinacalcet HCl were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 3, Table 4, and Table 5.
  • This inhibition test of Cinacalcet HCl on endocrine-related cancer cells were using prostate cancer cell lines PC-3 and LNCap (Table 6), breast cancer cell lines MCF7 and MDA-MB-231 (Table 7), and ovarian cancer cell lines NIH-OVCAR-3 and TOV-21G (Table 8).
  • the inhibitory tests of Cinacalcet HCl were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 6, Table 7, and Table 8.
  • This inhibition test of Cinacalcet HCl on gastrointestinal tract-related cancer cells were using gastric cancer cell lines AGS and MKN-45 (Table 9), hepatic cancer cell lines HepG2 and Hep3B (Table 10), colorectal cancer cell lines HCT116-wt and LoVo (Table 11), pancreatic cancer cell line AsPC-1 and BxPC-3(Table 12), tongue cancer cell line SAS (Table 13).
  • the inhibitory tests of Cinacalcet HCl were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 9, Table 10, Table 11, Table 12 and Table 13.
  • This inhibition test of Cinacalcet HCl on other cancer cells were using osteosarcoma cell line U2OS (Table 14), skin cancer cell lines A375 and BCC (Table 15).
  • the inhibitory tests of Cinacalcet HCl were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 14 and Table 15.
  • Cinacalcet HCl This inhibition test results of Cinacalcet HCl on all kinds of cells were shown in Table 18. Cinacalcet HCl is having different inhibitory effect on different tumor cell type even in the same cancer. As a result in the experiments of the present invention, Cinacalcet HCl has a significant inhibitory effect and specificity on various cancer cells. ( FIG. 1 )
  • mice were(BALB/cAnN.Cg-FoxnlTM/CrlNarl) and purchased from National Laboratory Animal Center (Taiwan). The weight of the mice were 21 ⁇ 1 g. These mice were subcutaneously injected with gastric cancer cells (AGS) and then put these mice into different cages at random. The drug test experiment was divided into three groups, include “control group”, “low dose group (100 mg/kg/day)”, “high dose group (200 mg/kg/day)”. These mice were then injected test drug intraperitoneally once daily until the tumor size reached 100 mm 3 . The tumor sizes and body weight were measured twice a week. The tumor sizes were measured and calculated by formula: (L ⁇ W 2 )/2. L represents the tumor longest length. W represents the tumor shortest diameter. The experiment result is shown in Table 19.
  • both low dose and high dose of Cinacalcet HCl had effectively slow down the tumor volume growth, and can also reduce the tumor volume.
  • high doses of Cinacalcet HCl had better effect to inhibit tumor growth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method for treating a cancer includes administering to a subject in need thereof a pharmaceutical composition containing a therapeutically effective amount of Cinacalcet HCl or a pharmaceutical acceptable salt thereof. The cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, a gastrointestinal tract-related cancer, osteosarcoma, skin cancer, and blood cancer.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This is a National Phase Application filed under 35 U.S.C. 371 as a national stage of PCT/CN2015/092776 filed Oct. 23, 2015, an application claiming the benefit under 35 USC 119(e) to the following U.S. Provisional Applications No. 62/068,298 filed Oct. 24, 2014, the content of each of which is hereby incorporated by reference in its entirety.
    • FIELD OF THE INVENTION
  • The present invention related to a new indication of Cinacalcet hydrochloride (Cinacalcet HCl) pharmaceutical composition, especially related to inhibition effect of Cinacalcet hydrochloride (Cinacalcet HCl) pharmaceutical composition on a variety of cancer cells.
    • BACKGROUND OF THE INVENTION
  • Cancer is the most popular disease cause of death in the world. The cancer patients are gradually increase yearly, therefore the treatment method of the cancer has become an important issue. The medical treatments of cancer can be classified as surgical treatment, radiation therapy, chemotherapy and target therapy.
  • Generally, the cancer drug, whether chemotherapy drug or target therapy drug, is to inhibit cancer cells duplication and split to prevent the tumor growth and metastasis.
  • More attention of therapies is being focused on drugs or other substances that block the growth and spread of cancer by interfering with specific molecules (“molecular targets”) that are involved in the growth, progression, and spread of cancer. Averagely, only about five of 10,000 new drugs can successfully enter the phase I of clinical trials.
  • Otherwise, the manufacturing of the drug is still a big problem. When the drug starting the clinical trials, there are lots of problems need to overcome, such as drug safety, patient selection, trial dose and other issues. Even the drug has approved by the FDA and sales on the market, there still possibly face the situation of the poor drug response in patients. Furthermore, if the cancer patients happen the drug resistance, that would reduce the effectiveness of the drugs and result in the medical treatment failure. Therefore, the new drug development is very difficult.
  • Cinacalcet hydrochloride (Cinacalcet HCl) or calcimimetic is a naphthalene derivative and calcimimetic agent that increases the sensitivity of parathyroid gland calcium-sensing receptors to serum calcium. (Cinacalcet HCl) is the orally bioavailable hydrochloride salt of the calcimimetic cinacalcet. Cinacalcet increases the sensitivity of calcium-sensing receptors on chief cells in the parathyroid gland to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion. In other word, these actions could reduce parathyroid hormone secretion and decreases serum calcium in the treatment of parathyroid disease. Further, a reduction in PTH levels inhibits osteoclast activity, which may result in a decrease in cortical bone turnover and bone fibrosis, and normalization of serum calcium and phosphorus levels. In another way, Cinacalcet HCl therapy was used for secondary hyperparathyroidism in hemodialysis patients. As a result, Cinacalcet HCl is approved by FDA and accumulated a huge data of drug use and drug mechanism research.
  • Due to the differences of the clinical use, there is no research present that the Cinacalcet HCl has any potential to inhibit cancer cell.
    • SUMMARY OF THE INVENTION
  • In order to solve the above problems, the present invention provides the development of new cancer clinical indications of Cinacalcet HCl.
  • Accordingly, the present invention provides a new indication of Cinacalcet HCl. The experimental results showed that the Cinacalcet HCl had no toxicity or had little toxicity to normal cells in the present invention. However, the selective effect of Cinacalcet HCl between normal cells and cancer cells need to be identified.
  • The present invention provides a pharmaceutical composition of Cinacalcet HCl for treating cancer. The pharmaceutical composition is composed of effective dose of Cinacalcet HCl and a pharmaceutical acceptable salt.
  • In one embodiment of the present invention, the cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer.
  • In one embodiment of the present invention, the cancer is selected from osteosarcoma, skin cancer and blood cancer.
  • In one embodiment of the present invention, the pleural-related cancer is lung cancer.
  • In one embodiment of the present invention, the abdominal-related cancer is selected from bladder cancer, and cervical cancer.
  • In one embodiment of the present invention, the endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer.
  • In one embodiment of the present invention, the gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.
  • In one embodiment of the present invention, the effective dose of Cinacalcet HCl is from 10 mg/kg/day to 500 mg/kg/day.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG 1 shows the inhibitory effect of Cinacalcet HCl on the different cancer cells.
  • FIG. 2 shows the results of the inhibitory effect of tumor volume by Cinacalcet HCl.
  • FIG. 3 shows the inhibitory effect of tumor growth via administered high-dose and low-dose of Cinacalcet HCl.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • Cell Culture
  • Subculture the different types of cancer cells. The cancer cells includes lung cancer, gastric cancer, hepatic cancer, colon cancer, skin cancer, cervical cancer, prostate cancer, bladder cancer, breast cancer, leukemia, pancreatic cancer, ovarian cancer, tongue cancer, osteosarcoma, and renal cancer. The normal cells used in the control group included kidney cell (HEK293) and human bronchial epithelial cell line BEAS-2B (as shown in Table 1).
  • Cancer cell lines were cultured in different culture medium according to different characteristics (as shown in Table 1). The cell numbers were counted and reseed as 2×106 in culture plate/flask. Then, the culture medium were added to a volume of 10 ml, and the cells were cultured for 2-3 days. Then, the cells were suspended for loading into 96-well plates. The number of cells was 3000 and the volume of the culture medium was 100 μl each well.
  • TABLE 1
    Cancer cell lines and culture medium
    No Cancer type Cancer cell type Culture medium
    1 lung cancer H1650 (lung adenocarcinoma) RPMI-1640
    A549 (lung adenocarcinoma) DMEM
    2 gastric cancer AGS (Gastric Adenocarcinoma) RPMI-1640
    MKN-45 (Gastric Adenocarcinoma) RPMI-1640
    3 hepatic cancer HepG2 (hepatocellular carcinoma) DMEM
    Hep3B (hepatocellular carcinoma) DMEM
    4 colon cancer HCT116(p53+) (colorectal carcinoma) DMEM
    LoVo(Colorectal Adenocarcinoma) DMEM
    5 skin cancer A375 (amelanotic melanoma) DMEM
    BCC (basal cell carcinoma) DMEM
    6 cervical cancer HeLa (Cervix Adenocarcinoma) DMEM
    C-33A (Cervical carcinoma) BCRC60554 MEM
    7 prostate cancer PC3 (p53−)(Prostate adenocarcinoma) DMEM
    LNCaP clone FGC (LNCap.FGC) RPMI-1640
    8 bladder cancer 8301 (urinary bladder carcinoma) RPMI-1640
    T24 RPMI-1640
    9 breast cancer MCF7 (Mammary Gland, Adenocarcinoma) DMEM
    MDA-MB-231 (Mammary Gland, Adenocarcinoma) DMEM
    10 pancreatic cancer BxPC-3 RPMI-1640
    AsPC-1 RPMI-1640
    11 ovarian cancer NIH: OVCAR-3 RPMI-1640
    TOV-21G RPMI-1640
    12 tongue cancer SAS (Tongue squamous cell carcinoma) DMEM
    13 osteosarcoma U-2OS DMEM
    14 renal cancer 786-O (Renal adenocarcinoma) BCRC 60243 RPMI-1640
    15 normal cell kidney HEK293 (Kidney) DMEM
    pulmonary epithelial BEAS-2B (Lung Epithelial) RPMI-1640
    cell line
  • Cell Viability Analysis
  • Removing the original culture medium from 96-well plate. Then add 100 μl of commercially drug at a concentration of 10 μM per well. After 72 hours, add the diluted WST-1 reagent to the well with 100 μl/well, and the diluted WST-1 reagent was acquired from the dilution of 9:1 medium and WST-1 stock reagent. Finally, the total volume of each well was 200 μl/well. Culture the 96-well plate at 37° C. for 30 to 90 minutes. Detecting and calculate the survival rate of each cancer cells with an ELISA reader at OD450 nm. The lower viability of cancer cells represents better inhibition effect via the Cinacalcet HCl drug. Otherwise, the higher viability of cancer cells represents worse inhibition effect via the Cinacalcet HCl drug.
  • The Effect of Cinacalcet HCl on Different Cancer Cell Lines
  • The Inhibition Effect of Cinacalcet HCl on Pleural-Related Cancer Cells
  • This inhibition test of Cinacalcet HCl on pleural-related cancer cells were using two lung cancer cell lines A549 and H1650. The inhibitory tests of Cinacalcet HCl were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 2.
  • TABLE 2
    The inhibition effect of Cinacalcet HCl on pleural-related cancer cells
    0524-10
    min 0526-10 min 0529-10 min 0531-10 min Average
    A549 87.7 102.7 75.5 92.6 89.6
    1-10 min 2-20 min 3-20 min 4-20 min Average
    H1650 86.8 67.5 76.8 75.2 76.5
  • The Inhibition Effect of Cinacalcet HCl on Abdominal-Related Cancer Cell Lines
  • This inhibition test of Cinacalcet HCl on abdominal-related cancer cells were using bladder cancer cell line TSGH and T24 (Table 3), cervical cancer cell lines HeLa and C-33A (Table 4), renal cancer cell line 786-O (Table 5). The inhibitory tests of Cinacalcet HCl were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 3, Table 4, and Table 5.
  • TABLE 3
    The inhibition effect of Cinacalcet HCl on bladder cancer cell lines
    0510-10
    min 0512-10 min 0515-10 min 0517-10 min average
    TSGH 57.3 73.2 74.7 33.9 59.8
    T24-1-30 T24-2-20 T24-3-20 T24-4-20
    min min min min average
    T24 71.1 132.6 177.1 103.3 121.0
  • TABLE 4
    The inhibition effect of Cinacalcet HCl on cervical cancer cell lines
    0524-10 0526-10 0529-10 0531-10
    min min min min average
    HeLa 109.6 118.6 104.1 113.0 111.3
    C-33A 114.5 118.8 108.1 100.0 110.3
  • TABLE 5
    The inhibition effect of Cinacalcet HCl on renal cancer cell lines
    0524-10 min 0526-10 min 0529-10 min 0531-10 min average
    786-O 81.3 71.6 80.2 87.1 80.0
  • The Inhibition Effect of Cinacalcet HCl on Endocrine-Related Cancer Cell Lines
  • This inhibition test of Cinacalcet HCl on endocrine-related cancer cells were using prostate cancer cell lines PC-3 and LNCap (Table 6), breast cancer cell lines MCF7 and MDA-MB-231 (Table 7), and ovarian cancer cell lines NIH-OVCAR-3 and TOV-21G (Table 8). The inhibitory tests of Cinacalcet HCl were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 6, Table 7, and Table 8.
  • TABLE 6
    The inhibition effect of Cinacalcet HCl on prostate cancer cell lines
    PC-3- PC-3- PC-3- PC-3-
    0524-10 0526-10 0529-10 0531-10
    min min min min average
    PC-3 102.7 132.2 120.3 134.6 122.5
    Average
    LNCap 52.6
  • TABLE 7
    The inhibition effect of Cinacalcet
    HCl on breast cancer cell lines
    0612-10 0614-10 0616-10 0619-10
    min min min min average
    MCF7 87.7  75.6  82.2  77.2  80.7 
    MDA- 92.35 84.94 60.81 92.75 82.71
    MB-231
  • TABLE 8
    The inhibition effect of Cinacalcet HCl on ovarian cancer cell lines
    7-3-30 min 7-4-30 min 7-7-30 min -4-30 min average
    NIH-OVCAR-3  90.7 111.1 100.2 111.0 103.3
    TOV-21G 128.7 109.4 104.1 108.2 112.6
  • The Inhibition Effect of Cinacalcet HCl on Gastrointestinal Tract-Related Cancer Cell Lines
  • This inhibition test of Cinacalcet HCl on gastrointestinal tract-related cancer cells were using gastric cancer cell lines AGS and MKN-45 (Table 9), hepatic cancer cell lines HepG2 and Hep3B (Table 10), colorectal cancer cell lines HCT116-wt and LoVo (Table 11), pancreatic cancer cell line AsPC-1 and BxPC-3(Table 12), tongue cancer cell line SAS (Table 13). The inhibitory tests of Cinacalcet HCl were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 9, Table 10, Table 11, Table 12 and Table 13.
  • TABLE 9
    The inhibition effect of Cinacalcet HCl on gastric cancer cell lines
    0510-10 0512-10 0515-10 0517-10
    min min min min average
    AGS 26.6  20.0  52.3 14.50856943 28.3
    MKN-45 82.1 101.5 103.6 69.1     89.1
  • TABLE 10
    The inhibition effect of Cinacalcet HCl on hepatic cancer cell lines
    0524-20 0526-20 0529-20 0531-20
    min min min min average
    HepG2 105.7 132.6 116.5  89.5 111.1
    0612-20 0614-20 0616-20 0619-20
    min min min min average
    Hep3B 143.2 125.1 151.5 116.8 134.1
  • TABLE 11
    The inhibition effect of Cinacalcet HCl on colorectal cancer cell
    lines
    0602-30 0605-10 0607-10 0609-10
    min min min min average
    HCT116-wt 89.0 107.3 132.5 112.6 110.3
    0616-10 0619-10 0621-10 0623-10
    min min min min average
    LoVo 73.9 125.0  90.4  84.2  93.4
  • TABLE 12
    The inhibition effect of Cinacalcet HCl on pancreatic cancer cell
    lines
    1-7-3-30 min 1-7-4-30 min 1-7-7-30 min 1-4-30 min Average
    AsPC-1 61.6 81.7  60.4 71.9 68.9
    3-7-3-30 min 3-7-4-30 min 3-7-7-30 min 3-4-30 min Average
    BxPC-3 64.6 78.8 100.1 76.2 79.9
  • TABLE 13
    The inhibition effect of Cinacalcet HCl on tongue cancer cell lines
    6-26-10 min 6-28-10 min 6-30-10 min 7-3-10 min average
    SAS 45.7 88.9 96.2 98.9 82.4
  • The Inhibition Effect of Cinacalcet HCl on Other Cancer Cell Lines
  • This inhibition test of Cinacalcet HCl on other cancer cells were using osteosarcoma cell line U2OS (Table 14), skin cancer cell lines A375 and BCC (Table 15). The inhibitory tests of Cinacalcet HCl were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated. The results were shown in Table 14 and Table 15.
  • TABLE 14
    The inhibition effect of Cinacalcet HCl on osteosarcoma cancer cell
    line
    6-26-10 min 6-28-10 min 6-30-10 min 7-3-10 min average
    U2OS 82.6 86.7 64.9 75.3 77.4
  • TABLE 15
    The inhibition effect of Cinacalcet HCl on skin cancer cell lines
    0602-30 min 0605-10 min 0607-10 min 0609-10 min average
    A375 117.1  95.6  94.4 108.5 103.9
    0602-30 min 0605-10 min 0607-10 min average
    BCC 114.2 105.5 112.6 110.8
  • The Experiment Design on Control Group
  • The Inhibition Effect of Cinacalcet HCl on Normal Cells
  • This inhibition test of Cinacalcet HCl on normal cells were using normal kidney cell line HEK293 (Table 16), normal pulmonary epithelial cell lines canine fibroblast cell line BEAS-2B (Table 17). The inhibitory tests of Cinacalcet HCl were performed 4 times for each cell lines and then the average value of the inhibitory tests was calculated The results were shown in Tables 16 and Tables 17.
  • TABLE 16
    The inhibition effect of Cinacalcet HCl
    on normal kidney cell line
    average
    HEK293 114.1
  • TABLE 17
    The inhibition effect of Cinacalcet HCl on normal pulmonary
    epithelial cell line
    0510-10 0512-10 0515-10 0517-10
    min min min min average
    BEAS-2B 70.5 72.9 72.2 89.0 76.1
  • This inhibition test results of Cinacalcet HCl on all kinds of cells were shown in Table 18. Cinacalcet HCl is having different inhibitory effect on different tumor cell type even in the same cancer. As a result in the experiments of the present invention, Cinacalcet HCl has a significant inhibitory effect and specificity on various cancer cells. (FIG. 1)
  • TABLE 18
    Summary of the Effect on different cancer
    cell lines by Cinacalcet HCl
    cancer cells Inhibitory effect
    lung cancer 83.09384194
    bladder cancer 90.4
    cervical cancer 111.32
    Kidney cancer 87.53
    prostate cancer 81.70
    breast cancer 107.9
    ovarian cancer 58.7
    gastric cancer 122.60
    hepatic cancer 101.85
    colorectal cancer 74.4
    pancreatic cancer 82.44
    tongue cancer 77.37
    osteosarcoma 107.32
    skin cancer 80.0
    kidney cell lines 114.06
    normal pulmonary epithelial 76.13
    cell line
  • Animal Model Test of Gastric Cancer with Dose 100 mg/kg/day and 200 mg/kg/day
  • In this invention, the female mice were(BALB/cAnN.Cg-Foxnl™/CrlNarl) and purchased from National Laboratory Animal Center (Taiwan). The weight of the mice were 21±1 g. These mice were subcutaneously injected with gastric cancer cells (AGS) and then put these mice into different cages at random. The drug test experiment was divided into three groups, include “control group”, “low dose group (100 mg/kg/day)”, “high dose group (200 mg/kg/day)”. These mice were then injected test drug intraperitoneally once daily until the tumor size reached 100 mm3. The tumor sizes and body weight were measured twice a week. The tumor sizes were measured and calculated by formula: (L×W2)/2. L represents the tumor longest length. W represents the tumor shortest diameter. The experiment result is shown in Table 19.
  • TABLE 19
    The inhibitory effect of tumor volume via administered Cinacalcet
    HCl
    control group Low dose (100 mg/kg/day) high dose (200 mg/kg/day)
    tumor tumor tumor
    longest vol- volume longest volume longest volume
    weight length width ume growth weight length width volume growth weight length width volume growth
    (g) mm mm mm3 mm3 (g) mm mm mm3 mm3 (g) mm mm mm3 mm3
    First measurement
    A 18.5 7 7 171.5 171.5 20 11 8 352 352 19 7 5 87.5 87.5
    B 22 8 6 144 144 16 13 8 416 416 19.5 6 6 108 108
    C 20.5 9 8 288 288 21 14 12 1008 1008 1.5 6 4 48 48
    aver- 20.4 7.6 7 189.3 189.3 592 592 81.16667 81.16667
    age
    Second measurement
    A 22 7 6 126 −45.5 21 8 5 100 −252 18.5 7 7 171.5 84
    B 20 8 7 196 52 22 16 8 512 96 21 6 7 147 39
    C 20 9 7 220.5 −67.5 19 9 7 220.5 −787.5 19 6 5 75 27
    aver- 20.6 8.4 6.8 198.5 9.2 277.5 −314.5 131.1667 50
    age
    Third measurement
    A 23 9 6 162 36 23.5 19 15 2137.5 2037.5 19 7 5 87.5 −84
    B 20 10 8 320 124 21 7 6 126 −386 22 6 5 75 −72
    C 21 11 7 269.5 49 21 8 6 144 −76.5 18.5 6 5 75 0
    aver- 21.2 10 6.8 235.3 36.8 802.5 525 79.16667 −52
    age
    Fourth measurement
    A 22 12 8 384 114.5 22 10 7 245 −1892.5 23 6 3 27 −60.5
    B 22 11 8 352 172 22 14 7 343 217 23 5 4 40 −35
    C 23 12 9 486 134 23 13 13 1098.5 954.5 20 0 0 0 −75
    aver- 22.4 295.7 62.2 562.1667 −240.3333 22.33333 −56.8333
    age
  • According to the results in FIG. 2, both low dose and high dose of Cinacalcet HCl had significant inhibition effect on tumor cells, and the weight of mice did not show a significant decrease during the experiment. These results indicated that both high and low doses of Cinacalcet HCl could keep the tested mice in healthy status during the treatment without death.
  • According to the results in FIG. 3, both low dose and high dose of Cinacalcet HCl had effectively slow down the tumor volume growth, and can also reduce the tumor volume. Especially, high doses of Cinacalcet HCl had better effect to inhibit tumor growth.
  • Although the present invention has been described in terms of specific exemplary embodiments and examples, it will be appreciated that the embodiments disclosed wherein are for illustrative purposes only and various modifications and alterations might be made by those skilled in the art without departing from the spirit and scope of the invention as set forth in the following claims.

Claims (8)

1. A method for treating a cancer comprising: administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of Cinacalcet HCl or a pharmaceutical acceptable salt thereof.
2. The method of claim 1, wherein the cancer is selected from the group consisting of a pleural-related cancer, an abdominal-related cancer, an endocrine-related cancer, and a gastrointestinal tract-related cancer.
3. The method of claim 1, wherein the cancer is selected from the group consisting of osteosarcoma, skin cancer, and blood cancer.
4. The method of claim 2, wherein the pleural-related cancer is lung cancer.
5. The method of claim 2, wherein the abdominal-related cancer is selected from the group consisting of bladder cancer, cervical cancer, and kidney cancer.
6. The method of claim 2, wherein the endocrine-related cancer is selected from the group consisting of prostate cancer, breast cancer, and ovarian cancer.
7. The method of claim 2, wherein the gastrointestinal tract-related cancer is selected from the group consisting of gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.
8. The method of claim 1, wherein the effective amount of Cinacalcet HCl is from 10 mg/kg/day to 500 mg/kg/day.
US15/521,504 2014-10-24 2015-10-23 New indication of cinacalcet hcl pharmaceutical composition for treating cancer Abandoned US20170304228A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/521,504 US20170304228A1 (en) 2014-10-24 2015-10-23 New indication of cinacalcet hcl pharmaceutical composition for treating cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068298P 2014-10-24 2014-10-24
PCT/CN2015/092776 WO2016062286A1 (en) 2014-10-24 2015-10-23 Uses of cinacalcet hcl in preparing pharmaceutical composition for treatment of cancer
US15/521,504 US20170304228A1 (en) 2014-10-24 2015-10-23 New indication of cinacalcet hcl pharmaceutical composition for treating cancer

Publications (1)

Publication Number Publication Date
US20170304228A1 true US20170304228A1 (en) 2017-10-26

Family

ID=55760314

Family Applications (7)

Application Number Title Priority Date Filing Date
US15/521,540 Active US10098852B2 (en) 2014-10-24 2015-10-23 Indication of monobenzone pharmaceutical composition for treating cancer
US15/521,524 Abandoned US20170304286A1 (en) 2014-10-24 2015-10-23 New indication of paroxetine pharmaceutical composition for treating cancer
US15/521,536 Abandoned US20170304388A1 (en) 2014-10-24 2015-10-23 New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition
US15/521,504 Abandoned US20170304228A1 (en) 2014-10-24 2015-10-23 New indication of cinacalcet hcl pharmaceutical composition for treating cancer
US15/521,517 Active US10105357B2 (en) 2014-10-24 2015-10-23 Indication of antibiotic drugs for preparation of cancer inhibition pharmaceutical composition
US15/521,500 Abandoned US20170312260A1 (en) 2014-10-24 2015-10-23 New indication of azelnidipine pharmaceutical composition for treating cancer
US15/492,859 Active US10045962B2 (en) 2014-10-24 2017-04-20 Uses of duloxetine HCL medicament in preparing pharmaceutical treatment of cancer

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US15/521,540 Active US10098852B2 (en) 2014-10-24 2015-10-23 Indication of monobenzone pharmaceutical composition for treating cancer
US15/521,524 Abandoned US20170304286A1 (en) 2014-10-24 2015-10-23 New indication of paroxetine pharmaceutical composition for treating cancer
US15/521,536 Abandoned US20170304388A1 (en) 2014-10-24 2015-10-23 New indication of cardiovascular drugs for preparation of cancer inhibition pharmaceutical composition

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/521,517 Active US10105357B2 (en) 2014-10-24 2015-10-23 Indication of antibiotic drugs for preparation of cancer inhibition pharmaceutical composition
US15/521,500 Abandoned US20170312260A1 (en) 2014-10-24 2015-10-23 New indication of azelnidipine pharmaceutical composition for treating cancer
US15/492,859 Active US10045962B2 (en) 2014-10-24 2017-04-20 Uses of duloxetine HCL medicament in preparing pharmaceutical treatment of cancer

Country Status (9)

Country Link
US (7) US10098852B2 (en)
EP (3) EP3222278B1 (en)
JP (1) JP6539345B2 (en)
KR (1) KR102490334B1 (en)
CN (3) CN106999470A (en)
AU (2) AU2015335391B2 (en)
ES (1) ES2954860T3 (en)
TW (21) TW201615194A (en)
WO (21) WO2016062291A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3708564A1 (en) 2005-12-28 2020-09-16 Vertex Pharmaceuticals Incorporated A solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2015335391B2 (en) * 2014-10-24 2018-06-21 Launx Biomedical Co., Ltd. Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer
AU2015370666B2 (en) 2014-12-22 2020-09-03 Arovella Therapeutics Limited Prevention and treatment of metastatic disease in thrombocytotic cancer patients
WO2017116049A1 (en) * 2015-12-31 2017-07-06 경북대학교 산학협력단 Pharmaceutical composition for treating cancer and suppressing metastasis, containing sulfonamide-based compound as active ingredient
EP3241562A1 (en) * 2016-05-02 2017-11-08 Fundació Institut Mar d'Investigacio Medica Zonisamide for use in the treatment of breast cancer
CN106074474A (en) * 2016-06-15 2016-11-09 中南大学湘雅医院 Benserazide and pharmaceutically application in terms of preparing antineoplastic for the acceptable salt
WO2018072135A1 (en) 2016-10-19 2018-04-26 微菌方舟生物科技股份有限公司 Use of dihydropyridine calcium antagonist in treating cancer
CN108066345A (en) * 2016-11-14 2018-05-25 武汉华杰世纪生物医药有限公司 A kind of compound with antitumor action
MX2019007391A (en) 2016-12-20 2019-08-16 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine.
EP3558276A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US20200179404A1 (en) * 2017-06-09 2020-06-11 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
WO2019008516A2 (en) * 2017-07-03 2019-01-10 Menri Group Ltd. Treatment of cancer with dihydropyridines
JP2019064976A (en) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 Anticancer agents
KR101933805B1 (en) 2017-10-17 2018-12-28 성균관대학교산학협력단 Pharmaceutical Composition for Preventing or Treating brain tumor comprising Oxeladin citrate as Active Ingredients
CN108186652A (en) * 2017-12-28 2018-06-22 深圳大学 Gap connects iuntercellular communication inhibitor 18-BETA-Glycyrrhetinic acid and is preparing the application in preventing and treating hepatocellular carcinoma drug
WO2019152475A1 (en) 2018-01-30 2019-08-08 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
WO2019204764A1 (en) * 2018-04-19 2019-10-24 Washington University Compositions and methods of use thereof for treatment of proteinopathies
WO2019243452A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
FR3090084B1 (en) 2018-12-18 2023-10-13 Securengy Projectile for firearms or compressed air for liquid or powder delivery.
US20220072089A1 (en) * 2018-12-19 2022-03-10 University Of Vermont And State Agricultural College Cancer therapeutic compositions and methods
CN113924090A (en) * 2019-04-04 2022-01-11 大邱庆北尖端医疗产业振兴财团 Pharmaceutical composition for preventing or treating cancer comprising trimebutine or pharmaceutically acceptable salt thereof as active ingredient
US20220202771A1 (en) * 2019-04-05 2022-06-30 University Of North Texas Health Science Center At Fort Worth Antidepressants for the Treatment or Prevention of Memory Loss and/or Cognitive Decline or Dysfunction in Aging
US20220146492A1 (en) * 2019-04-11 2022-05-12 Ian Basil Shine Cell membrane permeability restoring therapy
CN110179803A (en) * 2019-05-31 2019-08-30 天津科技大学 A kind of application of thioxanthene bromine class compound
CN110742890A (en) * 2019-10-24 2020-02-04 暨南大学 Application of lomerizine in preparation of anti-colon cancer drug
CN110840887A (en) * 2019-11-18 2020-02-28 杭州彗搏科技有限公司 Application of triclabendazole in preparation of medicine for treating breast cancer
CN110876800B (en) * 2019-11-18 2023-06-27 中南大学 Application of micafungin in preparation of antitumor drugs and antitumor drugs
CN111067899B (en) * 2020-01-08 2021-03-05 温州医科大学 Application of antimalarial primaquine phosphate in preparation of drugs for treating leukemia
US11304969B2 (en) * 2020-01-24 2022-04-19 The Florida International Univeristy Board Of Trustees Treatments of prostate cancer
CN111973593A (en) * 2020-05-09 2020-11-24 深圳市罗湖区人民医院 Application of nitazoxanide and pharmaceutically acceptable salt thereof in preparation of medicines for treating bladder cancer
CN111557941A (en) * 2020-06-15 2020-08-21 浙江大学 Application of small-molecule inhibitor minoxidil of PLOD2 in tumor treatment
CN111848717A (en) * 2020-08-07 2020-10-30 四川大学 Compound for targeted regulation of mitochondrial energy metabolism and application and medicament thereof
TW202214245A (en) * 2020-08-10 2022-04-16 國立彰化師範大學 Two non-cancer drugs pharmaceutical composition use of cancer treatment
CN112274525B (en) * 2020-12-04 2022-04-08 遵义医科大学 Chemotherapy pharmaceutical composition and application thereof
CN112336725A (en) * 2020-12-11 2021-02-09 吴照球 Novel medical application of trimethoprim
CN112569342A (en) * 2020-12-21 2021-03-30 中南大学 Application of caspofungin and/or pharmaceutical salt thereof in preparation of antitumor drugs and antitumor drugs
CN112569215A (en) * 2020-12-30 2021-03-30 东莞市人民医院 Application of domiphen bromide in preparation of medicine for preventing and treating colorectal cancer
EP4108244A1 (en) * 2021-06-25 2022-12-28 Universität Regensburg Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
CN113663071B (en) * 2021-06-28 2022-12-30 四川大学 Use of FBXL2 activator for preparing medicine for treating EGFR driven lung cancer
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
WO2023035200A1 (en) * 2021-09-09 2023-03-16 中国福利会国际和平妇幼保健院 Application of pentafluorite in preparation of drug for treating endometrial cancer
CN115887455B (en) * 2022-08-04 2024-04-05 北京大学人民医院 Application of azelnidipine serving as calcium channel blocker in preparation of medicines for treating endometrial cancer
CN116570579A (en) * 2023-06-13 2023-08-11 深圳市泛谷药业股份有限公司 Pharmaceutical composition containing agomelatine and fluvoxamine and application thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721335B1 (en) * 1993-10-01 2005-08-31 Roche Palo Alto LLC Mycophenolate mofetil high dose oral suspensions
KR100264348B1 (en) * 1994-12-28 2000-08-16 디르크 반테 Pharmaceutical composition containing nebivolol as an anti-atherogenic
AU746887B2 (en) * 1998-09-15 2002-05-02 Eli Lilly And Company Treatment of persistent pain
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
WO2002004406A2 (en) * 2000-07-07 2002-01-17 Trustees Of Tufts College 9-substituted minocycline compounds
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
GB0202337D0 (en) * 2002-02-01 2002-03-20 Univ Birmingham Cancer treatment
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CN1878556A (en) * 2003-09-18 2006-12-13 康宾纳特克斯公司 Combinations of drugs for the treatment of neoplasms
KR20060124607A (en) * 2003-11-06 2006-12-05 셀진 코포레이션 Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
EP1753425A4 (en) * 2004-05-12 2009-08-05 Biorunx Co Ltd A therapeutic agent containing nicotinic acid or its derivatives as an effective ingredient for prevention and treatment of cancer
DK1753713T3 (en) * 2004-05-21 2016-11-28 Harvard College SYNTHESIS OF TETRACYCLINES AND ANALOGS THEREOF
CN1279980C (en) * 2004-10-14 2006-10-18 孔庆忠 Anti solid tumor medicine composition
JP2006298781A (en) * 2005-04-15 2006-11-02 Geno Membrane:Kk Estrone-3-sulfate transporter activity inhibitor
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
CN101223149A (en) * 2005-07-05 2008-07-16 特瓦制药工业有限公司 Process for preparing valsartan
ES2661169T3 (en) * 2005-07-28 2018-03-27 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Monophenol, benzenediol, or sulfhydryl compounds for use in the treatment of melanomas
US8148356B2 (en) * 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
AU2007230724B2 (en) * 2006-03-23 2014-01-30 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
CN101099724A (en) * 2006-07-07 2008-01-09 上海复旦复华药业有限公司 Micronization femara and its composition
CN101103976A (en) * 2006-07-14 2008-01-16 海南盛科生命科学研究院 Oral medicinal composition containing anastrozole and preparation technology thereof
US20100273868A1 (en) * 2007-01-05 2010-10-28 Cornerstone Therapeutics Inc. R-Zileuton for Use in Conditions Associated with Increased 5-Lipoxygenase and/or Leukotriene Activity (EG Asthma)
CN101730526A (en) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 Nanoparticle comprising rapamycin and albumin as anticancer agent
CA2691196C (en) * 2007-06-21 2016-05-24 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
WO2009025854A1 (en) * 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CN100563645C (en) * 2007-12-06 2009-12-02 济南帅华医药科技有限公司 A kind of Beisalutin sustained-release implantation agent for the treatment of entity tumor
WO2009126274A2 (en) * 2008-04-08 2009-10-15 New York University School Of Medicine Methods and compositions for the treatment of cancers, such as melanomas and gliomas
CN101569624A (en) * 2008-04-29 2009-11-04 石药集团中奇制药技术（石家庄）有限公司 Application of amlodipine to preparation of medicaments for curing phoproliferative diseases
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
EP2303255A1 (en) * 2008-06-03 2011-04-06 Université Paris Diderot - Paris 7 Pharmaceutical compositions useful for the treatment of cancers, in particular acute myeloid leukemia and acute promyelocytic leukemia
CN101612400A (en) * 2009-07-22 2009-12-30 陈志龙 1 application of receptor antagonist in antitumor of angiotensin
CN101690816A (en) * 2009-08-16 2010-04-07 王丽燕 Medicinal composition of calcium-containing antagonist, A II receptor antagonist and statins
CN101991553B (en) * 2009-08-21 2015-02-25 北京以岭生物工程技术有限公司 Exemestane tablet and preparation method thereof
CN101863806B (en) * 2010-03-18 2013-02-13 湖北省医药工业研究院有限公司 Preparation method of medicine (R)-Bicalutamide for resisting prostatic cancer
WO2011146583A2 (en) * 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
JP5978424B2 (en) * 2010-07-29 2016-08-24 国立大学法人京都大学 Screening method for anticancer drugs
US20130261142A1 (en) * 2010-12-15 2013-10-03 Hung-Cheng Lai Compounds used for treating cancer and the use thereof
CN102631354B (en) * 2011-02-11 2015-01-21 广东泰禾医药科技有限公司 Pharmaceutical composition containing vitamin D and metformin
CN102688493B (en) * 2011-03-25 2014-09-10 鼎泓国际投资（香港）有限公司 Pharmaceutical composition containing resveratrol, resveratrol derivative and Bc1-2 inhibitor, and application thereof
CN102813643B (en) * 2011-06-10 2014-09-24 北京蛋白质组研究中心 Application of bumetanide in inhibition of hepatoma cell transfer
EP2760473A1 (en) * 2011-09-27 2014-08-06 Biomed Valley Discoveries, Inc. Compositions and methods of treating gliomas
CN109985228A (en) * 2011-11-10 2019-07-09 凯伊药品公司 Sensipar and its application method
CN102600077B (en) * 2012-03-29 2013-06-05 江苏豪森药业股份有限公司 Gemcitabine or gemcitabine salt nano-emulsion injecta and preparation method thereof
ES2384069B1 (en) * 2012-03-29 2013-07-04 Hospital Sant Joan De Déu Cinacalcet and neuroblastic tumors
CN103536607A (en) * 2012-07-10 2014-01-29 邵金辉 Anti-tumor effects of oxytetracycline, propafenone and dipyrone
WO2014018563A2 (en) * 2012-07-23 2014-01-30 The Board Of Trustees Of The Leland Stanford Junior University Methods for the treatment of cancer
WO2014036654A1 (en) * 2012-09-06 2014-03-13 Mcmaster University Compounds and methods for selectively targeting cancer stem cells
BR112015006176B1 (en) * 2012-09-21 2023-04-18 Intensity Therapeutics, Inc USE OF A THERAPEUTIC AGENT AND AN INTRACELLULAR PERMEATION ENHANCEMENT AGENT
AR092899A1 (en) * 2012-10-04 2015-05-06 Ab Science USE OF MASITINIB FOR THE TREATMENT OF CANCER IN SUB-POPULATIONS OF IDENTIFIED PATIENTS USING PREDICTION FACTORS
CN103356687B (en) * 2012-10-19 2016-06-01 厦门大学 The purposes of a kind of ivermectin and derivative thereof
CN105142631A (en) * 2013-01-14 2015-12-09 健康诊所有限公司 Cancer drug and uses
CN103933569B (en) * 2013-01-22 2017-01-11 复旦大学 Anti-lung cancer pharmaceutical composition, its application, pill case and package
EP2970145B1 (en) * 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
US20140271727A1 (en) * 2013-03-18 2014-09-18 National Yang-Ming University Method of using an antidepressant for increasing immunity of a subject and treating cancer
CN104161759B (en) * 2013-05-16 2019-10-08 中国科学院上海药物研究所 The anticancer usage of anagrelide and its derivative
CN103396419A (en) * 2013-08-13 2013-11-20 海宁市绿升医药科技有限公司 Tumour photodynamic therapy medicine dihydroporphin e6-15-ethyl ester and preparation method thereof
CN103536925B (en) * 2013-10-28 2015-07-01 中国医学科学院基础医学研究所 Application of cardiac glycoside compound in treatment of non-small cell lung cancer
CN103622975B (en) * 2013-11-07 2016-06-15 广东药学院 Glipizide application in preparation tumor
KR20160143775A (en) * 2014-04-08 2016-12-14 더 메서디스트 하스피틀 Inos-inhibitory compositions and their use as breast cancer therapeutics
AU2015335391B2 (en) * 2014-10-24 2018-06-21 Launx Biomedical Co., Ltd. Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bech et al., "Cinacalcet for Hypercalcemia Caused by Pulmonary Squamous Cell Carcinoma Producing Parathyroid Hormone-Related Peptide," Case Reports in Oncology 2012;5:1-8. *
Ito et al., "Gastric cancer associated with overexpression of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor in relation to tumor progression," J Gastroenterol 1997; 32:396-400. *
PubMed record for Cinacalcet Hydrochloride, created August 8, 2005. *

Also Published As

Publication number Publication date
TW201615220A (en) 2016-05-01
TW201615195A (en) 2016-05-01
TWI672150B (en) 2019-09-21
TW201615197A (en) 2016-05-01
WO2016062274A1 (en) 2016-04-28
AU2015335375B2 (en) 2020-09-10
CN106999470A (en) 2017-08-01
AU2015335375A1 (en) 2017-05-18
TWI663969B (en) 2019-07-01
WO2016062290A1 (en) 2016-04-28
WO2016062277A1 (en) 2016-04-28
EP3235497A1 (en) 2017-10-25
WO2016062271A1 (en) 2016-04-28
TW201615222A (en) 2016-05-01
AU2015335391A1 (en) 2017-06-01
EP3210604C0 (en) 2024-02-14
US10045962B2 (en) 2018-08-14
CN107106550A (en) 2017-08-29
ES2954860T3 (en) 2023-11-27
TW201615221A (en) 2016-05-01
TW201615184A (en) 2016-05-01
US20170216247A1 (en) 2017-08-03
WO2016062270A1 (en) 2016-04-28
TW201615191A (en) 2016-05-01
WO2016062283A1 (en) 2016-04-28
TWI652060B (en) 2019-03-01
EP3222278A4 (en) 2018-06-20
EP3222278C0 (en) 2023-06-14
TW201615192A (en) 2016-05-01
US20170304218A1 (en) 2017-10-26
JP2017532351A (en) 2017-11-02
US20170304286A1 (en) 2017-10-26
EP3210604A1 (en) 2017-08-30
WO2016062289A1 (en) 2016-04-28
AU2015335391B2 (en) 2018-06-21
TW201615193A (en) 2016-05-01
EP3222278A1 (en) 2017-09-27
WO2016062267A1 (en) 2016-04-28
EP3222278B1 (en) 2023-06-14
US20170312260A1 (en) 2017-11-02
WO2016062285A1 (en) 2016-04-28
JP6539345B2 (en) 2019-07-03
WO2016062278A1 (en) 2016-04-28
WO2016062266A1 (en) 2016-04-28
WO2016062286A1 (en) 2016-04-28
EP3210604B1 (en) 2024-02-14
TWI663984B (en) 2019-07-01
TW201615224A (en) 2016-05-01
TW201615189A (en) 2016-05-01
WO2016062281A1 (en) 2016-04-28
KR20170084034A (en) 2017-07-19
TW201615188A (en) 2016-05-01
TW201615219A (en) 2016-05-01
WO2016062269A1 (en) 2016-04-28
TW201615194A (en) 2016-05-01
US20170304387A1 (en) 2017-10-26
EP3210604A4 (en) 2018-06-27
KR102490334B1 (en) 2023-01-18
US20170304388A1 (en) 2017-10-26
CN107106523A (en) 2017-08-29
TW201615223A (en) 2016-05-01
WO2016062265A1 (en) 2016-04-28
TW201615217A (en) 2016-05-01
TW201615226A (en) 2016-05-01
WO2016062291A1 (en) 2016-04-28
TW201615218A (en) 2016-05-01
WO2016062287A1 (en) 2016-04-28
WO2016062272A1 (en) 2016-04-28
WO2016062279A1 (en) 2016-04-28
US10098852B2 (en) 2018-10-16
WO2016062288A1 (en) 2016-04-28
US10105357B2 (en) 2018-10-23
TWI621434B (en) 2018-04-21
EP3235497A4 (en) 2018-06-13
WO2016062275A1 (en) 2016-04-28
TW201615186A (en) 2016-05-01
TW201615196A (en) 2016-05-01
TW201615225A (en) 2016-05-01

Similar Documents

Publication Publication Date Title
US20170304228A1 (en) New indication of cinacalcet hcl pharmaceutical composition for treating cancer
Basso et al. Repurposing drugs for glioblastoma: from bench to bedside
WO2015178426A1 (en) Cancer stem cell proliferation inhibitor
Xuan et al. Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth Corrigendum in/10.3892/ijo. 2023.5583
CN115364231B (en) Pharmaceutical composition for enhancing anti-tumor effect of EZH2 inhibitor and application thereof
Bai et al. Inhibiting autophagy enhanced mitotic catastrophe-mediated anticancer immune responses by regulating the cGAS-STING pathway

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION